To improve the lives of people impacted by hypoparathyroidism through education, support, research, and advocacy. Learn more and get involved.
NEWS & EVENTS
For U.S. patients receiving NATPARA through the Special Use Program
For a limited time the presentations can be viewed here on the website.
AZP-3601 is currently in development for the treatment of hypoparathyroidism
The study will be conducted at the National Institutes of Health.